Meu SciELO
Serviços Personalizados
Artigo
Indicadores
- Citado por SciELO
Links relacionados
- Similares em SciELO
Compartilhar
Revista Cubana de Higiene y Epidemiología
versão On-line ISSN 1561-3003
Resumo
HERNANDEZ ORTEGA, Ania et al. Direct-acting Antiviral Therapy for Hepatitis C Virus Infection in Hemodialysis Patients. Rev. cuba. hig. epidemiol. [online]. 2023, vol.60 Epub 24-Jul-2023. ISSN 1561-3003.
Introduction:
Hepatitis C virus infection is common in hemodialysis patients and is considered endemic in these units. The treatment used consisted of pegylated interferon and ribavirin, a combination that presented levels of toxicity and low response. Current drugs bring better results.
Objectives:
To determine the efficacy and safety of direct-acting antiviral therapy for hepatitis C virus infection in patients with chronic renal failure on hemodialysis.
Methods:
Prospective descriptive study in 19 patients on hemodialysis and with virus C infection, belonging to "Dr. Mario Muñoz Monroy" Teaching General Hospital, from December 2020 to September 2021. All were prescribed for 12 weeks with Sofosbuvir® 400 mg plus Daclatasvir® 60 mg daily. The variables age, sex, liver fibrosis were characterized by the aspartate aminotransferase/platelet index, adverse reactions and viral response 12 weeks after treatment.
Results:
Infection predominated in the group of 51 to 60 years (36.84%). Most patients showed an aspartate aminotransferase/platelet ratio ≤ 0.5, corresponding to the absence of significant liver fibrosis (14 patients). A minority of patients reported adverse reactions. No cardiovascular or hepatic toxicity was demonstrated. All patients had an undetectable viral load 12 weeks after treatment.
Conclusions:
The combination of Sofosbuvir® with Daclatasvir® for the treatment of hepatitis C virus infection in patients with chronic renal failure undergoing hemodialysis was effective, well tolerated and safe.
Palavras-chave : hepatitis C; hemodialysis; direct-acting antivirals; Sofosbuvir®; Daclatasvir®.